02221 2200205 4500001002100000005001500021035002000036245030000056700001900356700011000375250003800485260000900523300003200532084001500564082001500579008003900594650009800633520126900731990001502000INLIS00000000001769620211004094544 a0010-0721002228 acDNA library construction and isolation of genes for candidate vaccine antigens from Chrysomya bezziana (the Old World Screwworm fly). /cVuocolo,Tony,Supriyanti, Florentina; Muharsini, Sri;[Research Institute for Veterinary Science Jalan R.E. Martadinata 30, P.O. Box 151 Bogor 16114 Indonesia] aMuharsini, Sri a[Research Institute for Veterinary Science Jalan R.E. Martadinata 30, P.O. Box 151 Bogor 16114 Indonesia] aJurnal Ilmu Ternak dan Veteriner. c2000 aVol.5 (3): p.160-169. 2000. aARTVET2042 aARTVET2042211004 | | |  4acDNA library, peritrophin, peritrophic membrane, Chrysomya bezziana, Lucilia cuprina, vaccine aThe construction and use of cDNA libraries for the isolation of genes encoding candidate antigens for use in a recombinant vaccine against Chrysomya bezziana is described. RNA was isolated and mRNA purified from first and third instar larvae of Chrysomya bezziana and used in the synthesis of two cDNA libraries in the bacteriophage vector ? ZAP express . These libraries were screened using Digoxigenin-labeled DNA probes obtained from two independent approaches. First, a homolog approach used probes designed from previously characterized peritrophic membrane genes identified from the related myiasis fly, Lucilia cuprina. Secondly, a de novo approach used amino-terminal and internal peptide sequence information derived from purified Chrysomya bezziana peritrophic membrane proteins to generate DNA probes. Three peritrophic membrane genes were identified and characterized. Chrysomya bezziana peritrophin-48 was identified using the homolog approach and, Chrysomya bezziana peritrophin-15 and Chrysomya bezziana peritrophin-42 were identified using the de novo approach. The identification of these genes as encoding candidate antigens against Chrysomya bezziana has allowed the production of recombinant proteins for use in vaccination trials. aARTVET2042